ArticleBlood science (Baltimore, Md.)2025
Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation.
Article in Blood science (Baltimore, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic graft-versus-host disease (cGVHD) is a major complication of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). In our previous studies, we speculated that cGVHD might be closely related to immune-mediated encephalopathy lesions; however, its involvement in the central nervous system (CNS) is exceedingly rare. We performed a retrospective nested case-control study of patients who underwent haplo-HSCT between January 2013 and June 2022 at our institution. In total, 87 patients with cGVHD who had their cerebrospinal fluid (CSF) tested were enrolled, of whom 43 showed evidence of CNS-cGVHD. In these patients, acute GVHD, CSF proteins, and oligoclonal bands were identified as risk factors for cGVHD onset. We combined these variables to establish a nomogram for the cumulative incidence of cGVHD. We found no statistically significant differences in overall survival, leukemia-free survival, or cumulative incidence of relapse between the cGVHD and control groups. However, a significant difference in non-relapse mortality (NRM) was observed. Multivariate analysis of 43 patients diagnosed with CNS-cGVHD showed that underlying diseases and CSF proteins were independently associated with CNS-cGVHD occurrence. In conclusion, the CSF profile may be associated with the onset of cGVHD and higher NRM in cGVHD following haplo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.